Children's Hospital of Philadelphia
Philadelphia, PA, United States
Dr. Canna cares for children with rheumatologic and Immune Dysregulation diseases. He also leads a translational research program committed to improving understanding and management of autoinflammatory diseases and cytokine storm syndromes. More specifically, their interest in the connections between inflammasome activation and cytokine storm disorders like Macrophage Activation Syndrome (MAS) has led to a focus on IL-18 as well as investigations of the Immune Synapse.
Friday, October 24, 2025
11:10 AM – 11:30 AM Central Time
Disclosure(s): Apollo Therapeutics: Consultant (Ongoing); Bristol-Myers Squibb(BMS): Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Novartis: Site PI for industry-sponsored trial (Terminated, December 1, 2024); PracticePoint CME: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Simcha Therapeutics: Consultant (Ongoing), In-kind provision of a reagent (Ongoing); Sobi: Consultant (Ongoing)
Friday, October 24, 2025
11:35 AM – 11:55 AM Central Time
Disclosure(s): Apollo Therapeutics: Consultant (Ongoing); Bristol-Myers Squibb(BMS): Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Novartis: Site PI for industry-sponsored trial (Terminated, December 1, 2024); PracticePoint CME: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Simcha Therapeutics: Consultant (Ongoing), In-kind provision of a reagent (Ongoing); Sobi: Consultant (Ongoing)
Friday, October 24, 2025
12:00 PM – 12:20 PM Central Time
Disclosure(s): Apollo Therapeutics: Consultant (Ongoing); Bristol-Myers Squibb(BMS): Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Novartis: Site PI for industry-sponsored trial (Terminated, December 1, 2024); PracticePoint CME: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Simcha Therapeutics: Consultant (Ongoing), In-kind provision of a reagent (Ongoing); Sobi: Consultant (Ongoing)
IL-18 as a Guide to the Evaluation and Management of Still's Disease
Monday, October 27, 2025
2:30 PM – 3:00 PM Central Time
Disclosure(s): Apollo Therapeutics: Consultant (Ongoing); Bristol-Myers Squibb(BMS): Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Novartis: Site PI for industry-sponsored trial (Terminated, December 1, 2024); PracticePoint CME: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Simcha Therapeutics: Consultant (Ongoing), In-kind provision of a reagent (Ongoing); Sobi: Consultant (Ongoing)
